Good news for those with dodgy knees. Primary safety endpoints...

Good news for those with dodgy knees.

Primary safety endpoints met and efficacy showing significant reduction in knee pain and improvement in cartilage volume in STEP trial for Progenza Sydney, Australia – 22 May 2017

Key points • Primary endpoint of safety and tolerability met • Significant, rapid and sustained reduction in knee pain in both Progenza groups • Significant improvement in cartilage volume compared to placebo • Positive signs of disease modification • Positive clinical data to support near term Progenza licensing opportunities in Japan